Roth MKM analyst Jonathan Aschoff maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $40 price target.
Roth MKM Maintains Buy on Moleculin Biotech, Maintains $40 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.